BioCentury | Jan 28, 2020
Company News

Jan. 27 Company Quick Takes: Enhertu meets in pivotal gastric cancer study; plus Biocon-Mylan, CMS, Lilly-Boehringer, Ningbo-Genentech

...pill from Boehringer Ingelheim GmbH and Eli Lilly and Co. (NYSE:LLY) combines Jardiance empagliflozin, Tradjenta linagliptin...
...EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 BioCentury Staff Jardiance, empagliflozin (BI-10773) Tradjenta, Trajenta, Trazenta, linagliptin (BI 1356) AstraZeneca...
BioCentury | Jun 14, 2019
Clinical News

June 13 Clinical Quick Takes: Roche's Gazyva meets in Phase II for lupus; plus Boehringer/Lilly, Savara and more

...stimulating other aspects of the immune system (see "Target Wide, Test Narrow in Lupus" ). Tradjenta...
...Boehringer Ingelheim GmbH (Ingelheim, Germany) and Eli Lilly and Co. (NYSE:LLY) said DPP-4 inhibitor Tradjenta linagliptin...
...RO5072759 (Compound #), RG7159 (Compound #), GA101 (Compound #), obinutuzumab (Generic) Molgradex nemorexant (ACT-541468) NKTR-358 RSLV-132 SEL-212 Tradjenta, Trajenta, Trazenta, linagliptin (BI 1356) Boehringer...
BioCentury | Jun 4, 2019
Company News

June 4 Company Quick Takes: Lilly's Emgality gets expanded indication; plus Vimizim, Zerbaxa and more

...accepted for review an NDA for a fixed-dose triple combination tablet of Jardiance empagliflozin, Tradjenta linagliptin...
BioCentury | Apr 10, 2019
Clinical News

Aetion, Brigham and Women's partnerships will inform FDA RWE standards

...the results of the CAROLINA cardiovascular outcomes trial. CAROLINA is a non-inferiority trial of Tradjenta linagliptin...
...Type II diabetes. Eli Lilly and Co. (NYSE:LLY) and Boehringer Ingelheim GmbH (Ingelheim, Germany) market Tradjenta...
BioCentury | Aug 3, 2018
Clinical News

Boehringer, Lilly's Tradjenta meets in first CV outcomes trial

...Boehringer Ingelheim GmbH (Ingelheim, Germany) and partner Eli Lilly and Co. (NYSE:LLY) said Tradjenta linagliptin met...
...companies partnered to develop and commercialize Tradjenta and other diabetes candidates under a 2011 deal. Tradjenta...
...estimated glomerular filtration rate (eGFR) Status: Phase IV data Milestone: NA Jennie Walters Tradjenta, Trajenta, Trazenta, linagliptin (BI 1356) Boehringer...
BioCentury | Jul 21, 2017
Preclinical News

Researchers suggest inhibiting DPP-4 could help treat colitis

...Merck & Co. Inc. (NYSE:MRK), Onglyza saxagliptin from AstraZeneca plc (LSE:AZN; NYSE:AZN), and Tradjenta/ Trajenta linagliptin...
BioCentury | Oct 24, 2016
Strategy

Lilly’s history lesson

...the pharma’s revenues by 2020. Holford did not provide an estimate for diabetes drug Tradjenta linagliptin...
BioCentury | Sep 26, 2016
Clinical News

Glyxambi empagliflozin/linagliptin regulatory update

...EMA’s CHMP recommended approval of Glyxambi empagliflozin/linagliptin from Boehringer and Eli Lilly to treat Type II...
...“coming months.” The tablet combines empagliflozin, a sodium glucose co-transporter-2 ( SGLT2 ) inhibitor, and linagliptin...
...and Lilly partnered to co-develop and co-commercialize a portfolio of diabetes candidates, including empagliflozin and linagliptin...
BioCentury | Sep 16, 2016
Company News

CHMP reverses on Ninlaro, also backs Lartruvo, Ibrance

...first-line therapy, to treat estrogen receptor-positive, HER2-negative breast cancer. CHMP also recommended approval of Glyxambi empagliflozin/linagliptin...
...secondary hyperparathyroidism. Glyxambi combines Jardiance empagliflozin, a sodium-glucose cotransporter-2 ( SGLT2 ) inhibitor; and Trajenta linagliptin...
...Boehringer and Lilly are co-developing and co-commercializing a portfolio of diabetes candidates including empagliflozin and linagliptin...
BioCentury | Jun 6, 2016
Clinical News

Jentadueto XR linagliptin/metformin extended release regulatory update

...FDA approved an NDA from Boehringer for Jentadueto XR linagliptin/metformin extended release as an adjunct to...
...warning for the risk of lactic acidosis. Jentadueto XR is an extended-release combination of Tradjenta linagliptin...
...Ingelheim GmbH , Ingelheim, Germany Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Jentadueto XR linagliptin/metformin...
Items per page:
1 - 10 of 121